Therakind Ltd
R&D/Manufacturing
- [email protected]
- Phone
- +442083466035
- Website
- https://www.therakind.com/
- Membership category
- Corporate
Third Floor, 314 Regents Park Road, London, N3 2JX, United Kingdom
Therakind Ltd at a glance
About Therakind Ltd
Therakind is a specialty pharmaceutical company dedicated to improving drug delivery and patient acceptability through proprietary technology to support differentiated product development. With three products approved in the US, EU, UK and MENA, the company has a strong track record of successful global development and regulatory approval.
In line with its mission to enhance the delivery of therapeutics, Therakind’s pipeline features DriDose® proprietary single- and multi-dose dry powder nasal delivery technology, which has been engineered with efficacy and simplicity in mind, from manufacturing to filling and patient usability.
Nasal delivery opens the possibility of non-invasive, fast-acting systemic drug delivery, targeted local drug delivery to the nose, and the increasingly promising delivery of drugs “nose to brain”. Moreover, dry powder formulations offer inherent stability advantages for a wide range of drugs, potentially eliminating the need for cold chain storage.
DriDose® devices are user-friendly for both patients and carers, with an intuitive design that requires minimal training and no requirement to coordinate breathing with device actuation. Featuring an innovative cartridge system, the platform supports reusability, reducing plastic waste and lowering costs. This sustainable approach aligns with the growing emphasis on environmental responsibility in healthcare.
The Dridose® system is protected by robust intellectual property (US, EU, China, Japan, Canada India and Brazil), ensuring market exclusivity and scope for additional IP when combined with both novel or well-established molecules.
DriDose® has been validated in humans with intranasal administration of a peptide drug. Vaccine delivery was also successfully evaluated in a non-clinical in vivo study. Multiple in vitro characterisation studies support consistent delivery and suitable nasal deposition. Preclinical programmes are progressing new nasal product candidates aimed at neurological disorders and cancer symptom management, alongside collaborations with third parties developing proprietary molecules. Therakind has also developed specialised intranasal devices to support in vivo studies.
Alongside its core nasal delivery work, Therakind is also seeking strategic partnerships to advance a novel intravenous antimicrobial agent, based on a protein and its associated peptide, both demonstrating potent antibacterial activity against drug-resistant bacteria listed as priority pathogens by the WHO. In vitro studies showed low cytotoxicity and strong bactericidal activity against both Gram-positive and Gram-negative bacteria. Moreover, a preliminary proof-of-concept in vivo study with the protein showed promising efficacy and safety results.
Therakind welcomes collaboration opportunities across both development areas.
